171 related articles for article (PubMed ID: 32187023)
21. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
Hyrcza MD; Martins-Filho SN; Spatz A; Wang HJ; Purgina BM; Desmeules P; Park PC; Bigras G; Jung S; Cutz JC; Xu Z; Berman DM; Sheffield BS; Cheung CC; Leduc C; Hwang DM; Ionescu D; Klonowski P; Chevarie-Davis M; Chami R; Lo B; Stockley TL; Tsao MS; Torlakovic E
Mod Pathol; 2024 Jan; 37(1):100384. PubMed ID: 37972928
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of pan-TRK immunohistochemistry in differentiating secretory carcinoma from acinic cell carcinoma of salivary gland-A systematic review.
Sharma P; Sivakumar N; Pandiar D
J Oral Pathol Med; 2023 Mar; 52(3):255-262. PubMed ID: 36207812
[TBL] [Abstract][Full Text] [Related]
23. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
[TBL] [Abstract][Full Text] [Related]
24. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
[TBL] [Abstract][Full Text] [Related]
25. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
26. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
28. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
29. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
Sholl LM; Zheng M; Nardi V; Hornick JL
Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
[TBL] [Abstract][Full Text] [Related]
30. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
[No Abstract] [Full Text] [Related]
31. Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.
Karakas C; Giampoli EJ; Love T; Hicks DG; Velez MJ
Diagn Pathol; 2024 Jan; 19(1):10. PubMed ID: 38200576
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
[TBL] [Abstract][Full Text] [Related]
33. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
Harrison BT; Fowler E; Krings G; Chen YY; Bean GR; Vincent-Salomon A; Fuhrmann L; Barnick SE; Chen B; Hosfield EM; Hornick JL; Schnitt SJ
Am J Surg Pathol; 2019 Dec; 43(12):1693-1700. PubMed ID: 31498178
[TBL] [Abstract][Full Text] [Related]
34. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
[TBL] [Abstract][Full Text] [Related]
35.
Bang H; Lee MS; Sung M; Choi J; An S; Kim SH; Lee SE; Choi YL
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741260
[TBL] [Abstract][Full Text] [Related]
36. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F
Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
[No Abstract] [Full Text] [Related]
38. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma.
Ye Q; Chen H; Han C; Peng Y; Huang X; Sun H; Wu Y; Albarracin CT; Middleton LP; Sahin AA; Huo L; Ding Q
J Clin Pathol; 2023 Aug; ():. PubMed ID: 37586834
[TBL] [Abstract][Full Text] [Related]
39. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
[TBL] [Abstract][Full Text] [Related]
40. High-grade salivary gland carcinoma with the ETV6-NTRK3 gene fusion: A case report and literature review of secretory carcinoma with high-grade transformation.
Asai S; Sumiyoshi S; Yamada Y; Tateya I; Nagao T; Minamiguchi S; Haga H
Pathol Int; 2021 Jun; 71(6):427-434. PubMed ID: 33848386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]